General information about company

Scrip code*540204
NSE Symbol*NOTLISTED
MSEI Symbol*NOTLISTED
ISIN*INE666Q01016
Name of companyEIKO LIFESCIENCES LTD
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved31-10-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange17-10-2025
Description of presentation currencyINR
Level of roundingLakhs
Reporting TypeQuarterly
Reporting QuarterSecond quarter
Nature of report standalone or consolidatedConsolidated
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year endedUnaudited
Segment ReportingMulti segment
Description of single segment
Start date and time of board meeting31-10-2025 16:45
End date and time of board meeting31-10-2025 17:30
Whether cash flow statement is applicable on companyYes
Type of cash flow statementCash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualificationDeclaration of unmodified opinion



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-07-202501-04-2025
Date of end of reporting period30-09-202530-09-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations1167.172238.32
Other income26.152.62
Total income1193.272290.94
2Expenses
(a)Cost of materials consumed1015.861561.7
(b)Purchases of stock-in-trade00
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade-144.16140.15
(d)Employee benefit expense 13.7426.29
(e)Finance costs9.9714.79
(f)Depreciation, depletion and amortisation expense25.550.86
(g)Other Expenses
1Other Expenses105.23182.58
Total other expenses105.23182.58
Total expenses1026.141976.37
3Total profit before exceptional items and tax167.13314.57
4Exceptional items 00
5Total profit before tax167.13314.57
6Tax expense
7Current tax35.3765.36
8Deferred tax7.3314.11
9Total tax expenses42.779.47
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations124.43235.1
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method4.045.1
16Total profit (loss) for period128.47240.2
17Other comprehensive income net of taxes00
18Total Comprehensive Income for the period128.47240.2
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent107.56198.98
Total profit or loss, attributable to non-controlling interests20.9141.22
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent107.56198.98
Total comprehensive income for the period attributable to owners of parent non-controlling interests20.9141.22
21Details of equity share capital
Paid-up equity share capital1372.091372.09
Face value of equity share capital1010
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations0.781.45
Diluted earnings (loss) per share from continuing operations0.781.45
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations0.781.45
Diluted earnings (loss) per share from continuing and discontinued operations0.781.45
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Statement of Asset and Liabilities

ParticularsHalf Year ended (dd-mm-yyyy)
Date of start of reporting period01-04-2025
Date of end of reporting period30-09-2025
Whether results are audited or unauditedUnaudited
Nature of report standalone or consolidatedConsolidated
Assets
1 Non-current assets
Property, plant and equipment2261.04
Capital work-in-progress0
Investment property0
Goodwill0
Other intangible assets0
Intangible assets under development0
Biological assets other than bearer plants0
Investments accounted for using equity method0
Non-current financial assets
Non-current investments720.5
Trade receivables, non-current0
Loans, non-current455.44
Other non-current financial assets200
Total non-current financial assets1375.94
Deferred tax assets (net)0
Other non-current assets0
Total non-current assets3636.98
2Current assets
Inventories209.87
Current financial asset
Current investments0
Trade receivables, current1453.51
Cash and cash equivalents808.69
Bank balance other than cash and cash equivalents0
Loans, current0
Other current financial assets0
Total current financial assets2262.2
Current tax assets (net)0
Other current assets366.92
Total current assets2838.99
3Non-current assets classified as held for sale0
4Regulatory deferral account debit balances and related deferred tax Assets0
Total assets6475.97
Total current assets2838.99
3Non-current assets classified as held for sale0
4Regulatory deferral account debit balances and related deferred tax Assets0
Total assets6475.97
Equity and liabilities
1Equity
Equity attributable to owners of parent
Equity share capital1372.09
Other equity4505.75
Total equity attributable to owners of parent5877.84
Non controlling interest63
Total equity5940.84
2Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current100.9
Trade Payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises0
Total Trade payable0
Other non-current financial liabilities0
Total non-current financial liabilities100.9
Provisions, non-current0
Deferred tax liabilities (net)96.23
Deferred government grants, Non-current0
Other non-current liabilities0
Total non-current liabilities197.13
Current liabilities
Current financial liabilities
Borrowings, current0
Trade Payables, current
(A) Total outstanding dues of micro enterprises and small enterprises0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises171.87
Total Trade payable171.87
Other current financial liabilities0
Total current financial liabilities171.87
Other current liabilities50.7
Provisions, current60.05
Current tax liabilities (Net)55.38
Deferred government grants, Current0
Total current liabilities338
3Liabilities directly associated with assets in disposal group classified as held for sale0
4Regulatory deferral account credit balances and related deferred tax liability0
Total liabilities535.13
Total equity and liabilities6475.97
Disclosure of notes on assets and liabilitiesTextual Information(1)

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars3 months/ 6 month ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-07-202501-04-2025
Date of end of reporting period30-09-202530-09-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
1Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1Speciality Chemicals & Pharma Intermediates1025.241865.46
2Logistics Services141.93372.86
Total Segment Revenue1167.172238.32
Less: Inter segment revenue00
Revenue from operations 1167.172238.32
2Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1Speciality Chemicals & Pharma Intermediates72.15116.57
2Logistics Services30.6160.34
Total Profit before tax102.76176.91
i. Finance cost9.9714.79
ii. Other Unallocable Expenditure net off Unallocable income-78.38-157.55
Profit before tax171.17319.67
3(Segment Asset - Segment Liabilities)
Segment Asset
1Speciality Chemicals & Pharma Intermediates3722.813722.81
2Logistics Services1057.881057.88
Total Segment Asset4780.694780.69
Un-allocable Assets1695.281695.28
Net Segment Asset6475.976475.97
4Segment Liabilities
Segment Liabilities
1Speciality Chemicals & Pharma Intermediates353.47353.47
2Logistics Services181.65181.65
Total Segment Liabilities535.12535.12
Un-allocable Liabilities00
Net Segment Liabilities535.12535.12
Disclosure of notes on segments

Other Comprehensive Income

Date of start of reporting period01-07-202501-04-2025
Date of end of reporting period30-09-202530-09-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2Income tax relating to items that will not be reclassified to profit or loss 0.000.00
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss 0.000.00
5Total Other comprehensive income0.000.00


Cash flow statement, indirect

ParticularsHalf Year ended (dd-mm-yyyy)
Date of start of reporting period01-04-2025
Date of end of reporting period30-09-2025
Whether results are audited or unauditedUnaudited
Nature of report standalone or consolidatedConsolidated
Part IBlue color marked fields are non-mandatory.
1Statement of cash flows
Cash flows from used in operating activities
Profit before tax314.57
2Adjustments for reconcile profit (loss)
Adjustments for finance costs14.79
Adjustments for decrease (increase) in inventories367.61
Adjustments for decrease (increase) in trade receivables, current-374.94
Adjustments for decrease (increase) in trade receivables, non-current0
Adjustments for decrease (increase) in other current assets86.66
Adjustments for decrease (increase) in other non-current assets0
Adjustments for other financial assets, non-current0
Adjustments for other financial assets, current0
Adjustments for other bank balances0
Adjustments for increase (decrease) in trade payables, current-159.6
Adjustments for increase (decrease) in trade payables, non-current0
Adjustments for increase (decrease) in other current liabilities-128.47
Adjustments for increase (decrease) in other non-current liabilities0
Adjustments for depreciation and amortisation expense50.84
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss0
Adjustments for provisions, current43.3
Adjustments for provisions, non-current0
Adjustments for other financial liabilities, current-75.52
Adjustments for other financial liabilities, non-current0
Adjustments for unrealised foreign exchange losses gains0
Adjustments for dividend income0
Adjustments for interest income52.58
Adjustments for share-based payments0
Adjustments for fair value losses (gains)0
Adjustments for undistributed profits of associates0
Other adjustments for which cash effects are investing or financing cash flow0
Other adjustments to reconcile profit (loss)0
Other adjustments for non-cash items0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships0
Total adjustments for reconcile profit (loss)-227.91
Net cash flows from (used in) operations86.66
Dividends received0
Interest paid0
Interest received0
Income taxes paid (refund)33.6
Other inflows (outflows) of cash0
Net cash flows from (used in) operating activities53.06
3Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses0
Cash flows used in obtaining control of subsidiaries or other businesses0
Other cash receipts from sales of equity or debt instruments of other entities0
Other cash payments to acquire equity or debt instruments of other entities0
Other cash receipts from sales of interests in joint ventures0
Other cash payments to acquire interests in joint ventures0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships0
Proceeds from sales of property, plant and equipment0
Purchase of property, plant and equipment0
Proceeds from sales of investment property0
Purchase of investment property0
Proceeds from sales of intangible assets0
Purchase of intangible assets0
Proceeds from sales of intangible assets under development0
Purchase of intangible assets under development0
Proceeds from sales of goodwill0
Purchase of goodwill0
Proceeds from biological assets other than bearer plants0
Purchase of biological assets other than bearer plants0
Proceeds from government grants0
Proceeds from sales of other long-term assets0
Purchase of other long-term assets0
Cash advances and loans made to other parties360.29
Cash receipts from repayment of advances and loans made to other parties0
Cash payments for future contracts, forward contracts, option contracts and swap contracts0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts0
Dividends received0
Interest received52.58
Income taxes paid (refund)0
Other inflows (outflows) of cash0
Net cash flows from (used in) investing activities-307.71
4Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries0
Payments from changes in ownership interests in subsidiaries0
Proceeds from issuing shares0
Proceeds from issuing other equity instruments0
Payments to acquire or redeem entity's shares0
Payments of other equity instruments0
Proceeds from exercise of stock options0
Proceeds from issuing debentures notes bonds etc0
Proceeds from borrowings0
Repayments of borrowings99.93
Payments of lease liabilities0
Dividends paid0
Interest paid14.79
Income taxes paid (refund)0
Other inflows (outflows) of cash0
Net cash flows from (used in) financing activities-114.72
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes-369.37
5Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents0
Net increase (decrease) in cash and cash equivalents-369.37
Cash and cash equivalents cash flow statement at beginning of period1178.06
Cash and cash equivalents cash flow statement at end of period808.69



Details of Impact of Audit Qualification

Whether results are audited or unauditedUnaudited
Declaration of unmodified opinion or statement on impact of audit qualificationDeclaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Consolidated resultsYes
Audit firm's nameWhether the firm holds a valid peer review certificate issued by Peer Review Board of ICAICertificate valid upto
1P S V JAIN & ASSOCIATESYes31-03-2026